bioMerieux buys AviaraDx in $60M deal
France's bioMerieux, a leading in vitro diagnostics firm, has acquired the privately-held AviaraDx, a US molecular in vitro diagnostics company, based in San Diego, California. AviaraDx' diagnostic tests, based on its proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D facility and a small sales and marketing team, as well as a high-complexity Clinical Laboratory Improvement Amendments certified service lab.
bioMerieux has paid $60.0 million for full ownership of AviaraDx, which it plans to keep as an independent legal entity called bioTheranostics. Richard Ding, the French firm's corporate vice president of business development and theranostics, has been named chief executive of the new entity. He will also continue to serve as a member of the bioMerieux management committee.
Products already on the market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze